Acquisition is expected to accelerate development and commercialization of Kolibri™ and expand Aptar Pharma’s respiratory drug delivery platform

Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strategic acquisition of PULMOTREE, a Munich, Germany-based life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs. The acquisition is expected to accelerate the development, industrialization and commercialization of PULMOTREE’s Kolibri™ Non-Propellant Liquid Inhaler (NPLI) platform.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.